The efficacy of acquired humoral and cellular immunity in the prevention and therapy of experimental fungal infections

L. Polonelli, A. Casadevall, Y. Han, F. Bernardis, T. N. Kirkland, R. C. Matthews, D. Adrian, M. Boccanera, J. P. Burnie, A. Cassone, S. Conti, J. E. Cutler, R. Frazzi, C. Gregory, S. Hodgetts, C. Illidge, W. Magliani, G. Rigg, G. Santoni

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

In the past two decades, numerous studies have documented the importance of acquired immunity for host defense against invasive fungal infections. There is widespread consensus in the field of medical mycology that cellular immunity is critical for successful host defense against fungi. However, in recent years several studies have established the potential efficacy of humoral immunity in host protection against two major fungal pathogens: Candida albicans and Cryptococcus neoformans. For C. albicans, antibodies to mannan, proteases and a heat shock proteins have been associated with protection against infection. Furthermore, anti-idiotypic antibodies to antibodies recognizing killer toxin from Pichia anomala and mimicking natural anti-killer toxin receptor antibodies can protect against C. albicans and other microorganisms. For C. neoformans, antibodies to the capsular glucuronoxylomannan have been shown to mediate protection in animal models of infection. Vaccines that induce protective antibodies have been shown to protect against experimental C. albicans and C. neoformans infection. In contrast, humoral immunity has not yet been demonstrated to mediate protection against Coccidioides immitis. For C. immitis, protection against infection is thought to rely on T cell mediated immunity, and the emphasis is on identifying the antigens that stimulate protective cellular immune responses and several candidate vaccines have been identified. These results provide encouragement for the view that acquired immune responses can be mobilized for the prevention and treatment of fungal infections.

Original languageEnglish
Pages (from-to)281-292
Number of pages12
JournalMedical Mycology
Volume38
Issue numberSUPPL. 1
Publication statusPublished - 2000

Fingerprint

Investigational Therapies
Mycoses
Adaptive Immunity
Humoral Immunity
humoral immunity
Cellular Immunity
cell-mediated immunity
Candida albicans
Cryptococcus neoformans
therapeutics
antibodies
Antibodies
Coccidioides
Coccidioides immitis
infection
Infection
Vaccines
Mycology
toxins
Mannans

Keywords

  • Antibody
  • Candida albicans
  • Coccidioides immitis
  • Cryptococcus neoformans

ASJC Scopus subject areas

  • Agricultural and Biological Sciences (miscellaneous)
  • veterinary(all)
  • Microbiology

Cite this

Polonelli, L., Casadevall, A., Han, Y., Bernardis, F., Kirkland, T. N., Matthews, R. C., ... Santoni, G. (2000). The efficacy of acquired humoral and cellular immunity in the prevention and therapy of experimental fungal infections. Medical Mycology, 38(SUPPL. 1), 281-292.

The efficacy of acquired humoral and cellular immunity in the prevention and therapy of experimental fungal infections. / Polonelli, L.; Casadevall, A.; Han, Y.; Bernardis, F.; Kirkland, T. N.; Matthews, R. C.; Adrian, D.; Boccanera, M.; Burnie, J. P.; Cassone, A.; Conti, S.; Cutler, J. E.; Frazzi, R.; Gregory, C.; Hodgetts, S.; Illidge, C.; Magliani, W.; Rigg, G.; Santoni, G.

In: Medical Mycology, Vol. 38, No. SUPPL. 1, 2000, p. 281-292.

Research output: Contribution to journalArticle

Polonelli, L, Casadevall, A, Han, Y, Bernardis, F, Kirkland, TN, Matthews, RC, Adrian, D, Boccanera, M, Burnie, JP, Cassone, A, Conti, S, Cutler, JE, Frazzi, R, Gregory, C, Hodgetts, S, Illidge, C, Magliani, W, Rigg, G & Santoni, G 2000, 'The efficacy of acquired humoral and cellular immunity in the prevention and therapy of experimental fungal infections', Medical Mycology, vol. 38, no. SUPPL. 1, pp. 281-292.
Polonelli L, Casadevall A, Han Y, Bernardis F, Kirkland TN, Matthews RC et al. The efficacy of acquired humoral and cellular immunity in the prevention and therapy of experimental fungal infections. Medical Mycology. 2000;38(SUPPL. 1):281-292.
Polonelli, L. ; Casadevall, A. ; Han, Y. ; Bernardis, F. ; Kirkland, T. N. ; Matthews, R. C. ; Adrian, D. ; Boccanera, M. ; Burnie, J. P. ; Cassone, A. ; Conti, S. ; Cutler, J. E. ; Frazzi, R. ; Gregory, C. ; Hodgetts, S. ; Illidge, C. ; Magliani, W. ; Rigg, G. ; Santoni, G. / The efficacy of acquired humoral and cellular immunity in the prevention and therapy of experimental fungal infections. In: Medical Mycology. 2000 ; Vol. 38, No. SUPPL. 1. pp. 281-292.
@article{a5efa1fd5a0143aaa8aafd9b3b096327,
title = "The efficacy of acquired humoral and cellular immunity in the prevention and therapy of experimental fungal infections",
abstract = "In the past two decades, numerous studies have documented the importance of acquired immunity for host defense against invasive fungal infections. There is widespread consensus in the field of medical mycology that cellular immunity is critical for successful host defense against fungi. However, in recent years several studies have established the potential efficacy of humoral immunity in host protection against two major fungal pathogens: Candida albicans and Cryptococcus neoformans. For C. albicans, antibodies to mannan, proteases and a heat shock proteins have been associated with protection against infection. Furthermore, anti-idiotypic antibodies to antibodies recognizing killer toxin from Pichia anomala and mimicking natural anti-killer toxin receptor antibodies can protect against C. albicans and other microorganisms. For C. neoformans, antibodies to the capsular glucuronoxylomannan have been shown to mediate protection in animal models of infection. Vaccines that induce protective antibodies have been shown to protect against experimental C. albicans and C. neoformans infection. In contrast, humoral immunity has not yet been demonstrated to mediate protection against Coccidioides immitis. For C. immitis, protection against infection is thought to rely on T cell mediated immunity, and the emphasis is on identifying the antigens that stimulate protective cellular immune responses and several candidate vaccines have been identified. These results provide encouragement for the view that acquired immune responses can be mobilized for the prevention and treatment of fungal infections.",
keywords = "Antibody, Candida albicans, Coccidioides immitis, Cryptococcus neoformans",
author = "L. Polonelli and A. Casadevall and Y. Han and F. Bernardis and Kirkland, {T. N.} and Matthews, {R. C.} and D. Adrian and M. Boccanera and Burnie, {J. P.} and A. Cassone and S. Conti and Cutler, {J. E.} and R. Frazzi and C. Gregory and S. Hodgetts and C. Illidge and W. Magliani and G. Rigg and G. Santoni",
year = "2000",
language = "English",
volume = "38",
pages = "281--292",
journal = "Medical Mycology",
issn = "1369-3786",
publisher = "Informa Healthcare",
number = "SUPPL. 1",

}

TY - JOUR

T1 - The efficacy of acquired humoral and cellular immunity in the prevention and therapy of experimental fungal infections

AU - Polonelli, L.

AU - Casadevall, A.

AU - Han, Y.

AU - Bernardis, F.

AU - Kirkland, T. N.

AU - Matthews, R. C.

AU - Adrian, D.

AU - Boccanera, M.

AU - Burnie, J. P.

AU - Cassone, A.

AU - Conti, S.

AU - Cutler, J. E.

AU - Frazzi, R.

AU - Gregory, C.

AU - Hodgetts, S.

AU - Illidge, C.

AU - Magliani, W.

AU - Rigg, G.

AU - Santoni, G.

PY - 2000

Y1 - 2000

N2 - In the past two decades, numerous studies have documented the importance of acquired immunity for host defense against invasive fungal infections. There is widespread consensus in the field of medical mycology that cellular immunity is critical for successful host defense against fungi. However, in recent years several studies have established the potential efficacy of humoral immunity in host protection against two major fungal pathogens: Candida albicans and Cryptococcus neoformans. For C. albicans, antibodies to mannan, proteases and a heat shock proteins have been associated with protection against infection. Furthermore, anti-idiotypic antibodies to antibodies recognizing killer toxin from Pichia anomala and mimicking natural anti-killer toxin receptor antibodies can protect against C. albicans and other microorganisms. For C. neoformans, antibodies to the capsular glucuronoxylomannan have been shown to mediate protection in animal models of infection. Vaccines that induce protective antibodies have been shown to protect against experimental C. albicans and C. neoformans infection. In contrast, humoral immunity has not yet been demonstrated to mediate protection against Coccidioides immitis. For C. immitis, protection against infection is thought to rely on T cell mediated immunity, and the emphasis is on identifying the antigens that stimulate protective cellular immune responses and several candidate vaccines have been identified. These results provide encouragement for the view that acquired immune responses can be mobilized for the prevention and treatment of fungal infections.

AB - In the past two decades, numerous studies have documented the importance of acquired immunity for host defense against invasive fungal infections. There is widespread consensus in the field of medical mycology that cellular immunity is critical for successful host defense against fungi. However, in recent years several studies have established the potential efficacy of humoral immunity in host protection against two major fungal pathogens: Candida albicans and Cryptococcus neoformans. For C. albicans, antibodies to mannan, proteases and a heat shock proteins have been associated with protection against infection. Furthermore, anti-idiotypic antibodies to antibodies recognizing killer toxin from Pichia anomala and mimicking natural anti-killer toxin receptor antibodies can protect against C. albicans and other microorganisms. For C. neoformans, antibodies to the capsular glucuronoxylomannan have been shown to mediate protection in animal models of infection. Vaccines that induce protective antibodies have been shown to protect against experimental C. albicans and C. neoformans infection. In contrast, humoral immunity has not yet been demonstrated to mediate protection against Coccidioides immitis. For C. immitis, protection against infection is thought to rely on T cell mediated immunity, and the emphasis is on identifying the antigens that stimulate protective cellular immune responses and several candidate vaccines have been identified. These results provide encouragement for the view that acquired immune responses can be mobilized for the prevention and treatment of fungal infections.

KW - Antibody

KW - Candida albicans

KW - Coccidioides immitis

KW - Cryptococcus neoformans

UR - http://www.scopus.com/inward/record.url?scp=0034511320&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034511320&partnerID=8YFLogxK

M3 - Article

C2 - 11204156

AN - SCOPUS:0034511320

VL - 38

SP - 281

EP - 292

JO - Medical Mycology

JF - Medical Mycology

SN - 1369-3786

IS - SUPPL. 1

ER -